Kratom Supplement Marketers Dispute FDA Warning, Ask For Review

In addition to a review of the advisory announced by FDA Commissioner Gottlieb, a trade group petitions the agency for a meeting to allow stakeholders "to correct misstatements and factual errors on the science regarding the safety and addiction potential of kratom."

The question mark in a number of

Kratom-containing dietary supplement manufacturers and marketers are asking FDA to recant its Nov. 14 consumer advisory about the ingredient, arguing the agency's information is inaccurate and casting the ingredient as a tool in helping curb narcotics abuse.

"The substantial gap between the publicly available evidence showing the safety of kratom, and the secretive and unsubstantiated conclusions of...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from United States

More from North America